Piera Capranzano

Cardiologist; PhD; Professor at University of Catania, Italy

[European Society of Cardiology Journals @ESC_Journals]

Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? Read this State-of-the-Art review in #EHJ 👉 https://t.co/izTvcZQG42

@RoccoMontone @ehj_ed

[EHJ Editor-in-Chief @ehj_ed]

Late gadolinium enhancement imaging and sudden cardiac death. Read more in the @EHJ at https://t.co/QPO01AH5cZ #CardiacImaging #SuddenCardiacDeath #GadoliniumEnhancement @ESCardio @ESC_Journals

[Nature Reviews Cardiology @NatRevCardiol]

New online! Immunometabolism in heart failure https://t.co/oOWVZHBW8D

[Marco Spagnolo @marcospagnolo21]

Evidence supporting abbreviated DAPT stems from broad ACS cohorts and may not be generalizable to STEMI. In our meta, short DAPT reduced major bleeding without compromising ischemic protection—yet findings are heterogeneous and based on one dedicated RCT. Robust data are needed.

[European Society of Cardiology Journals @ESC_Journals]

Clinical feasibility of a quick response code-based digital self-reporting of medication adherence: results in patients on ticagrelor therapy from the APOLLO-QR observational study 👉 https://t.co/mYrjJ96I1Z

#EHJDigital @BruiningNico @rafavidalperez @fwasselbergs @rbcasado

[JACC Journals @JACCJournals]

"High-risk plaque,” not “vulnerable plaque”? This new #JACCIMG statement explores challenges to the concept, advances in imaging & therapy, and the future of focal interventions. https://t.co/bpz7SHr1o3

@ron_waksman @GreggWStone @RoccoVergallo

[EHJ Editor-in-Chief @ehj_ed]

Myocardial dysfunction caused by sepsis is usually termed ‘sepsis-induced cardiomyopathy’. New review summarizes current knowledge.
https://t.co/8ZtXTYyxbu
#sepsis #cardiomyopathy #cardiotwitter @ESC_Journals @escardio

[PCRonline 🫀 @PCRonline]

#EuroPCR #ICYMI View this newly updated PCR-#EAPCI Textbook chapter on Optical Coherence Tomography (OCT)

Authors: Francesco Prati, Flavio Giuseppe Biccirè, @ziadalinyc, @Sticchi_Alex, Evelyn Regar, @PCapranzano

🔗 https://t.co/RzrvlpnOdA

#InterventionalCardiology #CardioEd

[PCRonline 🫀 @PCRonline]

The PCR-#EAPCI Textbook is pleased to announce a new Editor-in-Chief!

We warmly welcome @robebyrne to the role of Editor-in-Chief. His expertise and commitment to research & education will continue to establish the Textbook as a premium academic resource for the whole #interventionalcardiology community.

A heartfelt thank you to Stephan Windecker for his visionary leadership over the past few years. His dedication has been instrumental in shaping this key educational reference.

A special thank you and congratulations to @PCapranzano who will continue in the role of Deputy Editor.

🔗https://t.co/xrotQwtcLU

[EHJ Editor-in-Chief @ehj_ed]

Age-specific troponin thresholds: considerations for the fifth universal definition of myocardial infarction in EHJ.
https://t.co/GrxYPXRZV4
@ESCardio @ESC_Journals #age #5UDMI @johnwmcevoy

[Alessandro Sticchi @Sticchi_Alex]

The new updated #OCT chapter of the #EAPCI - @PCRonline textbook is out!! 🚀

A huge pleasure and honor to participate to this manuscript with an amazing group of authors @per_contro @FBiccire @ziadalinyc E. Regar @PCapranzano 🙏🏻

Enjoy it! Have a look:
https://t.co/nnqSOodaT6

[PCRonline 🫀 @PCRonline]

“BIO-PCI” the turning point of vascular interventions?
Explore minimal metal PCI strategies, BRS evidence and long-term case outcomes with @FlavioRibichini, @sbrugaletta, @PCapranzano and @JuanFIglesias1 during this #PCRwebinar.

Save the date ➡️ Monday 9 December 2024 | 4:00pm (UTC+1): https://t.co/RFDDOSm9lb

[Lorenzo Scalia @drlorenzoscalia]

📊🩸 In this propensity score-matched study, downstream cangrelor and upstream ticagrelor were associated with comparable rates of in-hospital clinical outcomes

https://t.co/Oe8KFyPWTR
@IJCardio

#Cangrelor #Ticagrelor #PCI #STEMI #CardioTwitter #IJC #P2Y12

[Antonio Greco @AGrecoMD]

Randomized trials of cangrelor did not focus on STEMI, nor did they directly compare cangrelor to ticagrelor (the current standard of care). What is the relative efficacy and safety of downstream cangrelor compared with ticagrelor pretreatment?https://t.co/dDI5vefINX

[PCRonline 🫀 @PCRonline]

#HeartFailure is a hot topic at #ESCCongress. That's why we're delighted to provide you with access to this brand 🆕PCR-#EAPCI Textbook 📕 chapter on Transcatheter Interventions for Chronic Heart Failure

by Andrea Ruberti, @DomAngellotti, Xavier Freixa, Lukas Hunziker, Anna Franzone, @MariannaAdamo1, @JavedButler1, @MarcoMetra @FabienPraz

Read it here for free via your My PCR account until 10 September only! ➡️https://t.co/ZnUTYaMn0E

#interventionalcardiology #TreatTR #TMVR

[EHJ Editor-in-Chief @ehj_ed]

Aspirin-free antiplatelet strategies after percutaneous coronary interventions. A State-of-the Art Review published in the latest issue of #EHJ

@DFCapodanno @PCapranzano @escardio @ESC_Journals #aspirin #PCI
https://t.co/ctFYa0Bf9a

[Giuseppe Andò @giuseppe_ando]

Monotherapy with P2Y12-I after DAPT: Filling gaps in evidence-International Journal of Cardiology https://t.co/6HjwndLf6g
•P2Y12-I or ASA post-PCI?
•Meaningful 39% MI⬇️ with P2Y12-I
@PCapranzano @FeliceGragnano @GargiuloG83 #CardioTwitter @SIC_CARDIOLOGIA @sicigise @PCRonline

[Felice Gragnano @FeliceGragnano]

An exciting and comprehensive review of the evidence on P2Y12-I monoTx after PCI by @PCapranzano and @DFCapodanno just published in #EHJ 💊

✅ Must read for next weekend! 📖

#CardioTwitter #Cardiology
@ehj_ed @ESC_Journals @escardio

[EHJ Editor-in-Chief @ehj_ed]

Aspirin-free antiplatelet strategies after percutaneous coronary interventions. A State-of-the-Art Review just published in #EHJ
@escardio @ESC_Journals #CardioTwitter @DFCapodanno

https://t.co/PGr8isilXl

[Davide Capodanno @DFCapodanno]

A thorough understanding of study designs, populations, treatments, results, and limitations of trials testing P2Y12 inhibitor monotherapy vs. DAPT or vs. aspirin is required to consider adopting this treatment in clinical practice. This review addresses the use of aspirin-free antiplatelet strategies among patients undergoing PCI without a concomitant indication for oral anticoagulation, providing an overview of clinical evidence, guideline indications, practical implications, ongoing issues, and future perspectives.
https://t.co/tOoafdGb2V